Tech Company Financing Transactions
MimiVax Funding Round
MimiVax closed a funding round on 1/12/2024. Backers included MEDA Angels, National Brain Tumor Society and The Sontag Foundation.
Transaction Overview
Company Name
Announced On
1/12/2024
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Proceeds Purpose
The company intends to use the funds to support the ongoing phase 2b clinical study, subsequent registration-related work and prepare the company for commercialization of SurVaxM for ndGBM.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Elm & Carlton St. MRC 105
Buffalo, NY 14263
USA
Buffalo, NY 14263
USA
Phone
Website
Email Address
Not Recorded
Overview
MimiVax is commercializing intellectual property developed at Roswell Park Cancer Institute (RPCI) through bench to bedside clinical translation. We are developing immunotherapeutic vaccines and targeted therapies for cancer treatment. SurVaxM is our lead drug pipeline agent.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Ciesielski
Chief Medical Officer
Robert Fenstermaker
VP - Bus. Development
Anil Goyal
VP - General Counsel
Scott Friedman
Browse more venture capital transactions:
Prev: 1/12/2024: Requity Homes venture capital transaction
Next: 1/12/2024: Canada Nickel Company venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs